BEYOND CHO - NON-MAMMALIAN HOSTS COULD BE THE FUTURE EXPRESSION SYSTEMS OF CHOICE FOR RECOMBINANT BIOTHERAPEUTICS

摘要

Over the last 30 years there have been tremendous advances in CHO cell culture process engineering. Novel process concepts, such as fed batch, perfusion and continuous cultures, evolved from a deep understand of CHO metabolic needs and extensive media/feed formulation development. This knowledge has led to large gains in protein productivity that can be captured with culture duration and/or scale. The biotechnology industry is consistently pressured to reduce cost of manufacturing and improve per batch productivity. Independent, but related to this burden, is the ability to support an ever growing patient population with high doses of therapeutic protein. As such, Biogen partnered with MIT to take a holistic view of the potential future of biomanufacturing to identify technologies that can make step changes in productivity and cost reduction. These efforts have cast doubt that CHO would be the optimal host in the future, whereas a non-mammalian host could be a key to realizing the most significant gains in productivity and reduction in cost of manufacturing.